{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-177774","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2022-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.363734+00:00","generated_at":"2026-06-25T00:24:42.785208+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Atea Pharmaceuticals stockholders elect three Class II directors, approve 'one year' say-on-pay frequency","bullets":["Elected Bruno Lucidi, Polly A. Murphy, and Bruce Polsky as Class II directors (over 55.7M votes each, no broker non-votes included).","Advisory vote on executive compensation frequency: ONE year approved with 59,857,505 votes for (99.4% of votes cast).","Ratification of KPMG LLP as independent auditor for 2022 passed with 71,630,493 votes for, 281,592 against, 35,490 abstain.","Approximately 86.41% of outstanding shares were represented at the meeting (71,947,575 shares of common stock)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-177774","json":"https://secwatch.observer/filing/0001193125-22-177774.json","markdown":"https://secwatch.observer/filing/0001193125-22-177774.md","text":"https://secwatch.observer/filing/0001193125-22-177774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312522177774/0001193125-22-177774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312522177774/d916865d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T00:24:42.785208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}